2,821 reports of this reaction
1.9% of all ERENUMAB AOOE reports
#10 most reported adverse reaction
INJECTION SITE PAIN is the #10 most commonly reported adverse reaction for ERENUMAB AOOE, manufactured by Amgen Inc. There are 2,821 FDA adverse event reports linking ERENUMAB AOOE to INJECTION SITE PAIN. This represents approximately 1.9% of all 151,566 adverse event reports for this drug.
Patients taking ERENUMAB AOOE who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is a less commonly reported adverse event for ERENUMAB AOOE, but still significant enough to appear in the safety profile.
In addition to injection site pain, the following adverse reactions have been reported for ERENUMAB AOOE:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 2,821 FDA reports for ERENUMAB AOOE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 1.9% of all adverse event reports for ERENUMAB AOOE, making it a notable side effect.
If you experience injection site pain while taking ERENUMAB AOOE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.